Physician profile
Kari Combs
NPI 1841953510
$2,755.37
in general payments reported to CMS, 2019-2025
18 companies · $856 in 2025
The $856 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $177 · 2023: $875 · 2024: $846 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,462 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,461.97 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $719.55 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $649.01 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $332.80 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $190.99 | 2023-2025 | |
| Exact Sciences Corporation | $185.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $146.54 | 2024-2025 | Voquezna |
| Amgen INC. | $135.79 | 2022-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.90 | 2022-2024 | Tradjenta, Jardiance, Synjardy |
| Lilly USA, LLC | $82.15 | 2023-2024 | Jardiance, Emgality, Mounjaro |
| Janssen Biotech, INC. | $48.27 | 2025 | Tremfya |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.83 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $29.35 | 2024 | |
| Xeris Pharmaceuticals, INC. | $27.15 | 2023-2024 | Gvoke Hypopen |
| Dexcom, INC. | $21.55 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $13.70 | 2024 | Freestyle Libre 3 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.57 | 2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $13.49 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Combs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.